Research programme: alpha-6 integrin antagonists - DyaxAlternative Names: Alpha-6 integrin antagonists research programme - Dyax
Latest Information Update: 06 Oct 2004
Price : $50 *
At a glance
- Originator University of Arizona
- Developer Dyax Corp.
- Class Antibodies
- Mechanism of Action Integrin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 06 Oct 2004 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 15 Jul 2002 Preclinical trials in Prostate cancer in USA (unspecified route)